Status:
UNKNOWN
Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
Lead Sponsor:
XiaoXi Lin
Conditions:
Infantile Hemangioma
Eligibility:
All Genders
Up to 6 years
Brief Summary
The purpose of this study is to assess the safety and efficacy of Timolol Maleate treatment for different depth of infantile hemangioma based on B-ultrasonography. Based on the depth of hemangioma, pa...
Detailed Description
Primary: Describe the efficacy of 0.5% topical timolol maleate drops in different depth of infantile hemangioma as assessed through IB-ultrasound.
Eligibility Criteria
Inclusion
- Infants of 0 to 6 months of age
- Skin Infantile hemangiomas (IHs) in the proliferation stage without prior treatment
- IHs with a surface area of less than 1% of body surface area
- Skin type III/IV
Exclusion
- Ulcerated IHs.
- Unsuitable for topical Timolol treatment due to anatomical location of lesion, eg.
- periorbital and lip IHs.
- Patients with severe systemic or congenital disease which may affect the patient's safety in this study
Key Trial Info
Start Date :
February 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03842631
Start Date
February 16 2019
End Date
December 1 2020
Last Update
February 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200011